Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma

Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma: A Pilot Study

Endometrial carcinoma represents the most common gynaecological cancer and the sixth most frequent cancer among women worldwide. The 5-year survival of patients with stage I endometrial carcinoma is 75%-88% versus 50% for stage III or 15% for stage IV disease. Therefore, early detection could improve survival rates. Specifically, in the most prevalent, type 1 endometrial cancer develops from hyperplastic endometrium. The aim of the study was to evaluate the utility of cancer gene mutations from endometrial biopsies towards predicting synchronous or metachronous development of malignant lesions. The aim of the study was to evaluate whether endometrial biopsies could already carry mutations in cancer genes useful for predicting or anticipating subsequent cancer development

Inclusion Criteria:

• age > 18 years old
• patients subjected to endometrial biopsies with previous histopathologically negative and subsequent histopathologically positive for endometrial carcinoma
• patient informed consent

Exclusion Criteria:

- Endometrial carcinoma patients without a previous non-tumour biopsy were excluded